Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation

PHASE3CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

June 30, 2019

Study Completion Date

June 30, 2019

Conditions
Transient Ischemic AttackStrokeAtrial Fibrillation
Interventions
DRUG

Apixaban

DRUG

Warfarin

Trial Locations (5)

33602

Tampa General Hospital, Tampa

University of South Florida, Tampa

33701

Bayfront Health St Petersburg, St. Petersburg

40202

University of Louisville, Louisville

90502

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

University of South Florida

OTHER